BOT 2.21% 33.3¢ botanix pharmaceuticals ltd

Ann: FDA Approves Sofdra, page-277

  1. 4,164 Posts.
    lightbulb Created with Sketch. 5429
    Understood, you are quoting a hypothetical net sales figure that was used by BOT as a hypothetical. They never said it would be that, and it's not net profit so you can't use it to calculate PE. My point was it cannot possibly be net profit as Tax alone is bigger than the margin.

    BOT did say the price would command a higher value than competitors which are $690 a month. So we have a definante gross sales at least starting in the 700's.

    When calculating PE, it's based on overall company profit and that needs to take into account all costs ( not just sales cost)

    Having said that now, we are miles away from sales so SP could do anything in the meantime. It will respond to market demand, that should be good while we await Q4.

 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
33.3¢
Change
-0.008(2.21%)
Mkt cap ! $606.3M
Open High Low Value Volume
34.0¢ 34.0¢ 33.0¢ $620.9K 1.863M

Buyers (Bids)

No. Vol. Price($)
11 213435 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
33.5¢ 701613 11
View Market Depth
Last trade - 12.25pm 08/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.